AVERY MARZULLA-DULFER: Open Payments
NPI 1639453988 · NEW HAVEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$370 in 7 payments from 7 companies in 2025. Trend: 2023 $262 · 2024 $78 · 2025 $370
Food & beverage: $370
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. | 1 | $125 |
| GENZYME CORPORATION | 1 | $125 |
| ARRAY BIOPHARMA INC | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Novartis Pharmaceuticals Corporation | 1 | $22 |
| Iovance Biotherapeutics, Inc. | 1 | $19 |
| ABBVIE INC. | 1 | $19 |
Products named: Lenvima, SARCLISA, LORBRENA, DATROWAY, SCEMBLIX, Amtagvi, EMRELIS.
Industry payments across CT — which companies pay providers there.
